GlassScriptPhysician profile
David P Desai
NPI 1740451566
$26,540.45
in general payments reported to CMS, 2019-2025
34 companies · $6,479 in 2025
The $6,479 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,721 · 2020: $1,004 · 2021: $3,255 · 2022: $4,323 · 2023: $4,626 · 2024: $4,133 · 2025: $6,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,231.93 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,932.03 | 2019-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,758.65 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,649.51 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $2,456.06 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $2,328.51 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $1,826.36 | 2019-2022 | |
| Alkermes, INC. | $1,621.13 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,485.88 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,275.82 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,052.10 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $947.86 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $675.84 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $669.28 | 2021-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $584.24 | 2022-2025 | Xelstrym, Secuado |
| Indivior INC. | $546.23 | 2019-2024 | Perseris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $481.48 | 2019-2024 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $395.11 | 2019-2022 | |
| Allergan, INC. | $360.34 | 2019-2020 | |
| Corium, LLC | $335.83 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $306.03 | 2023-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $286.40 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $237.60 | 2022-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $78.89 | 2025 | Jornay Pm |
| Luye Pharma (USA) LTD. | $42.58 | 2025 | Erzofri Extended-Release |
| Tris Pharma INC | $30.78 | 2024-2025 | Dyanavel Xr |
| Janssen Scientific Affairs, LLC | $26.15 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.49 | 2022 | |
| Eisai INC. | $24.13 | 2025 | |
| Noven Pharmaceuticals, INC. | $22.81 | 2024 | Xelstrym |
| Bausch Health US, LLC | $18.90 | 2020 | |
| Tonix Medicines, INC. | $16.50 | 2025 | Tonmya |
| Arbor Pharmaceuticals, INC. | $15.89 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2020 | |
| Shire North American Group INC | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.